retatrutide real name FDA Approval Status 2026: Everything We Know So Far image.cfm?name=04.jpg&id=906833

Discovery The development of GLP-1 based drugs for obesity did not happen overnight

Injectable semaglutide exhibited the most substantial decrease in albuminuria in SUSTAIN-6, following by favourable results from liraglutide and dulaglutide in their separate cardiovascular outcome studies (Mansoor, et al

Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database

Across the 52 weeks of ATTAIN-MAINTAIN, participants treated with orforglipron gained an average of 5 kg (11 lbs) in the tirzpatide group and an average of 1 kg (2.2 lbs) in the semaglutide group